Raymond James Initiates Coverage On Odyssey Therapeutics with Outperform Rating, Announces Price Target of $42

Benzinga · 2d ago
Raymond James analyst Thomas Deal initiates coverage on Odyssey Therapeutics (NASDAQ:ODTX) with a Outperform rating and announces Price Target of $42.